The Oncology Institute of Hope and Innovation is a leader in clinical studies, with the goal to advance the treatment of cancer. We conduct more trials than most other community cancer groups in the US. Our research helps us evaluate the effectiveness of treatment, reduce the risk of complications, lower costs and save resources, and continually refine our clinical approach to cancer care.
Ph 1a/1b Study of ONC-392 (Anti-CTLA-4 mAb) Alone and in Combination with Pembrolizumab in Advanced Solid Tumors (Melanoma and NSCLC)
Request InformationPh 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer that is is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens.
Request InformationPh 3 Study of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer and an Intermediate-High Risk of Recurrence with Completed Definitive Locoregional Therapy and 2+ years of Standard Adjuvant Endocrine-Based Therapy without Disease Recurrence (CAMBRIA-1 / NSABP B-62)
Request InformationPh 3 Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab versus Investigator’s Choice of Therapy in Stage I-III Triple-negative Breast Cancer with Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Request InformationPh 3 Study of Eftilagimod Alpha (soluble LAG-3) in HER2-Neg/Low Metastatic Breast Cancer Receiving Paclitaxel
Request InformationPh 1 Study of ZN-A-1041 (HER-2 Inhibitor) Enteric Capsules as a Single Agent or in Combination in HER2-Positive Advanced Solid Tumors
Request InformationPh 1b/2 Study LBL-007 (anti-LAG-3) plus Tislelizumab in Combination with Bevacizumab plus Fluoropyrimidine Versus Bevacizumab plus Fluoropyrimidine as Maintenance Therapy in Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Request InformationPh 2 Study of Topically Administered LUT014 (Topical B-Raf Inhibitor) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.
Request InformationORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation
Request InformationPh 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-102)
Request InformationPh 2 Study of Customized Ibrutinib Treatment Regimens for Chronic Lymphocytic Leukemia (TAILOR)
Request InformationPh 2 Study of Asciminib (BCR::ABL1 kinase inhibitor) monotherapy in 2nd and 1st Line Chronic Phase- Chronic Myelogenous Leukemia (ASC2ESCALATE)
Request InformationPh 3 Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Request InformationPh 3 Study of CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM)
Request InformationPh 3 Study of Selinexor, Pomalidomide and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide and Dexamethasone (EloPd) in Relapsed or Refractory Multiple Myeloma (RRMM)
Request InformationPh 3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab and Carboplatin Versus Pembrolizumab plus Platinum-based Chemotherapy for the First-line Treatment of Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (AVANZAR)
Request InformationPh 3 Study of Zimberelimab and Domvanalimab plus Chemotherapy Versus Pembrolizumab plus Chemotherapy for 1L Treatment of Metastatic NSCLC With No EGFR or ALK Genomic Tumor Aberrations
Request InformationPh 2 Study of Combination Therapies with Adagrasib in Advanced NSCLC with KRAS G12C Mutation
Request InformationPh 3 Study of ONC-392 (Anti-CTLA-4 mAb) Versus Docetaxel in Metastatic NSCLC that Progressed on PD-1/PD-L1 Inhibitors
Request InformationPh 1/2 Study of Cemiplimab (Anti-PD-1 Antibody) + BNT116 (Fixvac Lung) Versus Cemiplimab Alone in First-Line Treatment of Advanced NSCLC expressing PD-L1 >50%
Request InformationPh 3 Study of Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab in completely resected Stage IIB, IIIA, or Select IIIB, PD-L1 positive NSCLC who have received adjuvant platinum-based chemo
Request Information"A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)"
Request InformationPh 2b Study of ZEN003694 with Enzalutamide versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Request InformationPh 3 study of Disitamab vedotin plus Pembrolizumab versus Chemotherapy in Previously untreated locally advanced or metastatic HER2+ Urothelial Carcinoma (IHC 1+ and greater)
Request Information
